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4 scores correlated moderately with the Visual Analogical Scale
of the EQ-5D. The dimensions which measure secondary effects
of immunosupression (Side Effects of Corticosteroids-SEC and
Increased Growth of Gum and Hair-IGGH) showed low corre-
lation with SF-36 and EQ-5D although they correlated with the
episodes of acute rejection (r > 0.4). The correlations with clin-
ical variables were low, but in accordance with expectations. The
correlations of the scores at 3 and 6 months were moderate (r =
0,7). 6 patients suffered initial allograft dysfunction and these
showed worse scores than the rest. Cronbachxs Alpha, which
evaluate the reliability, were: 0.92 for the whole questionnaire;
0.86, LPC; 0.79, LCC; 0.66, CRD; 0.63, SEC; 0.74, IGGH; 0.78,
TAPD. CONCLUSIONS: The feasibility, validity and reliability
of the Spanish version of the ESRD-scl were adequate to evalu-
ate the PHS of kidney transplant bearers.
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OBJECTIVES: To demonstrate the contribution of problems
associated with an overactive bladder; namely continence,
urgency and frequency, on health related quality of life and
utility. METHODS: Patients treated by an academic urology unit
in the UK were sent a self-completed survey that included the
EQ5D and SF36 and urology disease-speciﬁc questions. Poten-
tially confounding factors were controlled using multivariate
linear regression analysis. The survey was undertaken with the
Health Outcomes Data Repository (HODaR) framework, a large
representative dataset linking clinical data to routine QoL and
utility survey responses. RESULTS: In a routine survey without
reminders, 609 surveys were retuned (28% response rate). The
mean age of respondents was 65 years (SD 15.5) and 68% were
male. Sixty percent of valid responses reported some degree of
incontinence. Of these, 60% reported stress incontinence; 85%
had urinary frequency problems and 91% had urgency. Among
the generally continent: 12% reported stress incontinence; 60%
reported frequency problems and 54% reported urgency. Con-
trolling for age, gender and body mass index (BMI), incontinence
was associated with a reduction in the EQ5Dindex (-0.11; SE
0.026, p < 0.001) and SF36 scores across all domains (max:
physical role -14.51 (SE 3.92; p < 0.001)). Under similar ana-
lytic conditions in continent respondents, urgency signiﬁcantly
reduced social and mental-role functioning (-8.55; p = 0.069 &
-14.51; p = 0.080, respectively) whilst frequency reduced the
energy domain (-9.09; p < 0.05). Among the incontinent,
urgency reduced social functioning by -17.61 (p < 0.05), and the
mental domain by -11.58 (p < 0.05) whilst frequency again
reduced the energy domain by -9.07 (p < 0.05). CONCLU-
SIONS: Incontinence has a detrimental impact on quality of life
comparable with diseases and conditions traditionally regarded
as being more serious. Urinary urgency reduces social function-
ing and mental well-being, whilst increased urinary frequency
increases tiredness.
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OBJECTIVE: The I-QOL is a 22-item incontinence-speciﬁc
measure originally developed in the USA and subsequently
adapted into numerous other language versions. The British-
English language version has not yet been validated. The purpose
of this presentation is to report the psychometric performance
characteristics of the UK version of the I-QOL. METHODS: The
I-QOL was included in a cross-sectional, descriptive health out-
comes study among female care-seekers at 17 large primary care
clinics throughout the UK. A total of 2400 women between 18
and 91 years of age took the survey while waiting to be seen by
their care providers. Twenty-two percent (n = 503) of these
women reported symptoms of stress urinary incontinence; 21%
(n = 538) mixed; and 4% (n = 85) urge incontinence without
overactive bladder. Other measures included the Scale for Activ-
ity Interference and Limitation (SAIL, incontinence-speciﬁc indi-
vidualized activity limitations), the Symptom Frequency and
Bothersomeness scale (SFB-SUI), self-perceived severity, self-
reported episodes, and a variety of other demographic and
descriptive variables. Psychometric testing was conducted using
standardized procedures. Reproducibility could not be assessed
within the study design. RESULTS: Principal component analy-
ses conﬁrmed the original measurement model of three subscales
(avoidance and limiting behavior, psychosocial impacts, and
social embarrassment) and a total summary score. Internal con-
sistency values were acceptable (alpha ranged between 0.87 and
0.95) and, as hypothesized, the I-QOL had strong associations
with both the SFB-SUI (symptoms) (>0.60) and the SAIL (limi-
tations) (>0.67) scales. Quality of life scores became signiﬁcantly
worse as the patients’ perception of severity increased (p < 0.001)
and number of incontinent episodes increased (p < 0.001). CON-
CLUSION: This cross-sectional assessment of the British-English
version has shown it to have similar psychometric performance
to those previously published for the original measure, making
this I-QOL language version a valid PRO for incorporation in
community based studies of patients with varying types and
severity of urinary incontinence.
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OBJECTIVES: To investigate the impact of long-term treatment
with darifenacin, a muscarinic M3 selective receptor antagonist,
on quality of life (QoL) in patients with overactive bladder
(OAB). METHODS: Patients with OAB for ≥6 months who par-
ticipated in two 12-week, placebo-controlled, double-blind
feeder studies of darifenacin controlled release 3.75, 7.5 or 15
mg qd were enrolled into this 2-year, multicentre, open-label
extension. During the ﬁrst 2 weeks of the extension all patients
received darifenacin 7.5mg, after which titration between dar-
ifenacin 15 and 7.5mg was permitted. The King’s Health Ques-
tionnaire [KHQ] was used to assess QoL. Here, we report data
from patients who received darifenacin 7.5 or 15mg during the
feeder studies and had a gap of £3 treatment days before enter-
ing the extension. RESULTS: A total of 303 patients who had
received darifenacin 7.5 or 15mg during the feeder studies
entered the extension (22–89 years; 86.5% female) and 199
patients (65.7%) completed the study. Darifenacin 7.5/15mg
was associated with signiﬁcant improvements in eight of nine
KHQ domains (Incontinence impact, Severity measures, Role
limitations, Physical limitations, Social limitations, Emotions,
Personal relationships and Sleep/energy) from baseline to the end
of the 12-week, double-blind feeder studies (all p < 0.001 vs.
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feeder study baseline). These changes were maintained or further
improved during the open-label extension, such that signiﬁcant
improvements (p < 0.001 vs. feeder study baseline) were
observed for darifenacin 7.5/15mg in the same eight KHQ
domains after a further 24 months of treatment. Darifenacin was
well tolerated and the overall long-term safety proﬁle was con-
sistent to that observed in the 12 week phase III studies. CON-
CLUSIONS: Darifenacin signiﬁcantly improves QoL in patients
with OAB, with improvements maintained for 2 years during
open-label treatment.
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OBJECTIVE: To develop and validate a unique tool speciﬁc to
urinary incontinence (UI) symptoms covering all types of incon-
tinence among both men and women. METHODS: An Advisory
Committee (AC) of 5 urologists was set up, involved at all stages
of questionnaire development and validation. A test question-
naire was developed by AC with content validity being assessed
simultaneously on 3 men, 4 women suffering from UI and 3 clin-
icians. Clinicians were asked to comment items’ relevance and
comprehensiveness; patients completed the scale and were asked
to provide general comments regarding the scale and detailed
comments regarding each element. The scale was redrafted and
tested on 25 other patients. A longitudinal, multi-centre, anony-
mous, observational study was carried out to validate the scale.
The scale was administrated by 21 urologists to 258 stable
patients (206 UI sufferers and 52 not UI sufferers) until June 15th
2005. Patients ﬁlled in the scale, the ICIQ-SF and a diary twice
at one-week interval and clinicians completed a medical form at
baseline. RESULTS: The test scale contained 11 items covering
urge, SUI, dysuria and pollakiuria. After initial cognitive debrief-
ing and comments of patients and clinicians, 3 items were sig-
niﬁcantly modiﬁed. The pilot questionnaire still included 11
items. The validation study allowed assessing the internal con-
sistency reliability, the test-retest reliability and the clinical valid-
ity of the scores. CONCLUSION: For the ﬁrst time,
psychometric properties were established for a simple-to-use,
unique and UI speciﬁc symptom scale for men and women. This
new instrument could be helpful for use in everyday medical
practice and in clinical research.
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OBJECTIVES: The International Prostatic Symptom Score
(IPSS) evaluates the frequency of symptoms associated with
lower urinary tract symptoms (LUTS). An eighth question (q8)
evaluates the patient’s overall satisfaction dealing with his
urinary tract status but does not study in detail his bothersome-
ness. The SPI score (Symptom Problem Index) evaluates the
degree of discomfort associated with each question on the IPSS.
Our objective was to determine the relations between IPSS, SPI
and quality of life IPSS item (q8) scores. METHODS: A cohort
of 907 male patients with BPH has been monitoring by French
general practitioners. The IPSS and SPI self-administered ques-
tionnaires have been evaluated on the 722 patients with com-
plete data. Relationships between SPI, IPSS and q8 have been
investigated through the correlation between those scores and by
showing the individual answers dispersion of IPSS and SPI scores
when one was ﬁxed. RESULTS: The mean IPSS score was 12.6
+/- 6.4, the mean SPI score was 12.2 +/- 6.5. The correlation
coefﬁcient between the IPSS and SPI scores was 0.70 ; the scores
from the two rating scales showed a very high variability. Q8
was also weakly related to SPI (r = 0.56) and to IPSS (r = 0.57).
The response to the question on quality of life corresponded to
highly varying SPI and IPSS scores. CONCLUSIONS: IPSS and
SPI questionnaires do not collect the same information. One
scale cannot be replaced by another. Quality of life question of
the IPSS questionnaire isn’t enough to capture all the aspects of
bothersomeness explored by the SPI questionnaire. Among
patients suffering from LUTS, the joint use of the IPSS and SPI
seems appropriate.
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OBJECTIVE: Since stress incontinence episodes frequency is
highly related to maintenance or avoidance of activities causing
leakages, the additional beneﬁt of therapeutic options might be
difﬁcult to capture. Our objective was to develop a new speciﬁc
and sensitive endpoint to evaluate treatment effects in Stress
Urinary Incontinence (SUI) in clinical trials. METHODS: A com-
prehensive list of efforts provoking leakages was established
from a systematic literature review and 30 clinician interviews.
The list was updated according to comments collected during 8
semi-structured clinicians interviews. Clinicians were asked
about the relevance, comprehensiveness, and ability of the listed
activities to capture changes. They also reported how their
patients managed to control the risk of leakage. Twenty SUI
women were asked to assess the relevance, importance, and
applicability of each effort, to reword the list and to describe
with their own words how they control the risk of leakage. The
scale was ﬁnalised according to their comments. RESULTS: A
list of 72 daily life efforts provoking leakage was set from 15 UI
speciﬁc scales and 21 studies selected from the literature. The
clinician interviews allowed to group similar concepts and to
establish a shortlist containing the 15 most relevant efforts.
Answer choices covered the occurrence of leakage, and various
behaviour adaptation such as seeking help, taking precautions,
muscular control, and avoiding situations. After validation of
format, items, wording, and answer choices, by the patients, the
pilot scale was produced. CONCLUSION: This self-reported
scale allows SUI patients to accurately describe their control on
leakage risk in daily life efforts. This highly speciﬁc instrument
will allow clinicians to better assess the true impact of thera-
peutics on patients’ life, in both clinical research and clinical
practice. The scoring procedure and its properties will be
assessed in a speciﬁc validation study.
